Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal Czech Filtered by asset CI

Coverage 166,705 Raw stories ingested 21,933 rewritten in CS_CZ • 0 to rewrite (last 2 days).

Symbols 2,793 Assets with fetched stories

Cryptocurrencies BTC 7,350 ETH 4,859 XRP 3,279 SOL 2,984 HYPE 1,761 USDC 1,589

Stocks NVDA 1,794 SPCX 1,457 MU 1,327 MSFT 1,297 AAPL 1,062 TSLA 1,027

Commodities GOLD 550 SILVER 294 OIL 101 PLATINUM 14 PALLADIUM 4 COPPER 3

Forex EURUSD 499 GBPUSD 378 USDCAD 150 USDJPY 146 AUDUSD 99 USDCHF 63

2,195 with rewritten stories in CS_CZ • Hot assets ranked by fetched stories.

Agents 7 waiting Pipeline agents

FMP Stock News Fetch every minute 55s ago
FMP Forex News Fetch every 5 min 2m ago
CoinGecko News Fetch every 5 min 4m ago
FIO Stock News Fetch every 10 min 2m ago
Patria Stock News Fetch every 10 min 2m ago
Editorial rewrite Rewrite every minute 55s ago
Asset sync Assets every 1 hour 31m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

Category Source Ticker

Relevance

Clear

Details	Date	Content	Source	Relevance
	Saved 2026-08-31 11:14 9d ago Published 2026-08-27 11:21 13d ago	Cigna spouští Smart Coverage pro kryté zdravotní události Cigna Healthcare spouští Smart Coverage, které může oprávněným členům nabídnout až 7 000 USD na kryté úrazy, nemoci nebo hospitalizace. Zavedení začne 1. ledna 2027 pro klienty v USA s 500 až 2 999 zaměstnanci. CI Cigna	FMP Stock News	78
Original source text Key Takeaways Cigna's Smart Coverage may provide eligible members up to $7,000 for covered health events.Simple File Sync Plus automatically matches qualifying medical claims with supplemental benefits.Smart Coverage launches Jan. 1, 2027, for U.S. clients with 500 to 2,999 employees. The Cigna Group’s (CI - Free Report) health benefits arm, Cigna Healthcare, is linking medical and supplemental health benefits through a new connected experience designed to make cash support easier to access for costly health events. Its Medical with Smart Coverage option can be added to qualifying high-deductible health plans and may provide eligible members up to $7,000 for covered injuries, illnesses or hospitalizations. Cigna is also rolling out Simple File Sync Plus, which automatically matches qualifying medical claims with eligible supplemental benefits, reducing paperwork and missed claims. Smart Coverage launches Jan. 1, 2027, for U.S. clients with 500 to 2,999 employees at launch, with broader availability planned for 2028. The move targets a clear affordability gap in employer health coverage. Cigna and Ipsos found nearly 60% of Americans are not financially prepared for a health event, while 44% have spent at least $1,000 out of pocket after a diagnosis, injury or hospitalization. Fewer than one-third understand that supplemental benefits can also cover everyday costs including groceries, housing or child care. Meanwhile, half of workers with employer-sponsored medical coverage were offered a high-deductible plan in 2024, versus 38% in 2015. Cigna says employees are more than 2.5 times likelier to enroll when supplemental benefits are available alongside them today. The launch could strengthen Cigna’s employer offering by making high-deductible plans easier to sell and supplemental coverage easier to use. That may support client retention, new account wins and higher participation in supplemental products, creating incremental premium and fee opportunities over time. How Are Peers Placed?UnitedHealth Group Incorporated (UNH - Free Report) and Elevance Health, Inc. (ELV - Free Report) offer solutions that are similar to the connected-benefits approach. UnitedHealthcare’s Benefit Ally combines medical coverage with accident, critical-illness and hospital-indemnity benefits. For qualifying medical events, the system can automatically identify eligibility and trigger supplemental payouts, reducing or eliminating the need for employees to file separate claims. UnitedHealth also has Benefit Assist, which uses integrated medical-claims data to initiate supplemental claims. Elevance is doing something similar through Anthem. Its Whole Health Connection links Anthem medical coverage with accident, critical-illness and hospital-indemnity plans. When medical claims indicate that a member may qualify for a supplemental benefit, Anthem automatically alerts the member. CI’s Price Performance, Valuation and EstimatesShares of Cigna have gained 2% year to date, underperforming the broader industry’s growth of 22.1%. Image Source: Zacks Investment Research From a valuation standpoint, Cigna trades at a forward price-to-earnings ratio of 8.67X, down from the industry average of 16.13X. CI carries a Value Score of A. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Cigna’s 2026 earnings implies 2.3% growth year over year, followed by a 9.5% improvement next year. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
	Saved 2026-08-22 00:21 18d ago Published 2026-08-21 16:42 19d ago	Mark Cuban: AI nahradí administrativu ve zdravotnictví Mark Cuban tvrdí, že AI nenahradí radiology, ale hlavně administrativu ve zdravotnictví. Podle něj ji už nasazují CVS, Cigna a UnitedHealth. CI Cigna	FMP Stock News	78
Original source text This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Earlier this week, Mark Cuban weighed in on one of the year’s louder debates in medicine with a post on X: “No chance radiologists get replaced. A model is outdated the minute it is released. Model usage costs money. A lot more than a radiologist. Medicine is a business. Putting together AI with domain knowledge is complex.” The post stands out because it argues against AI replacing a specialty on cost and liability grounds rather than on capability grounds. Cuban’s logic is worth pulling apart. Foundation models drift the moment they ship. Inference at clinical scale carries a real per-query bill. And, in his framing, medicine is a business in which the combination of AI and domain expertise is genuinely hard to assemble. Where Cuban Thinks the Automation Actually Lands Earlier the same morning, Cuban drew the other side of the line in a separate post: “AI will replace most doctors [sic] tasks! Because most of their tasks are [expletive removed] administrivia introduced by the huge HC conglomerates that serve no purpose.” Read together, the two posts describe one position. Clinical judgment under liability and cost pressure stays. Administrative paperwork, in his view, does not have to. The administrative layer Cuban is describing is concentrated in a handful of vertically integrated, publicly listed companies, most visibly in the pharmacy benefit manager (PBM) business. A PBM sits between drug manufacturers, insurers, pharmacies, and patients, negotiating prices, setting formularies, and processing claims. Critics call PBMs middlemen; the companies argue they hold down drug costs. CVS Health (NYSE:CVS \| CVS Price Prediction) owns Caremark. In Q2 2026, Health Services revenue reached nearly $52 billion, and CEO David Joyner told investors CVS had launched an AI-enabled claims-assist manager that will reduce processing time by over 20% and accelerate payment for providers on hundreds of millions of claims every year. Aetna executive Steve Nelson said Aetna 1 advocates who used to spend 90 minutes preparing a case now take only two minutes. Shares are up 21% year to date. Cigna (NYSE:CI) owns Express Scripts inside Evernorth. Q2 2026 Evernorth revenue was $61.5 billion, though pharmacy benefit services pre-tax adjusted earnings came in at $609 million, down year over year as Cigna invests in its rebate-free Signature model. CEO Brian Evanko said Cigna’s Pharmacy Forward program uses AI to cut time to therapy in half on average and reduce clinician documentation time by up to 50%. Shares are roughly flat year to date. And of course, UnitedHealth Group (NYSE:UNH) owns Optum Rx. UnitedHealthcare committed to eliminating 30% of prior authorization volume and nearly two-thirds of prior authorization requirements for pediatric care by year-end, and targets processing 80% of prior authorizations in real time by the end of 2027. Optum’s digital prior auth product reports 96% first-pass approval. Q2 revenue was $112 billion. Shares are up 18% year to date. Consider the Source, Then Consider the Argument Cuban co-founded Mark Cuban Cost Plus Drug Company, which was built to bypass the PBM layer with transparent pricing, so he of course has a viewpoint on this. And also – the three conglomerates are already deploying AI against the exact administrative work Cuban says should go. Whether that compresses their margins or expands them is the open question for investors holding these names. Cuban’s framing inverts the usual AI-disruption story: the specialists may keep their jobs; the administrative layer that pays for a lot of enterprise value at CVS, Cigna, and UnitedHealth may not keep all of its scope. Contact [email protected] for any questions or corrections.
	Saved 2026-08-19 18:53 21d ago Published 2026-08-19 12:46 21d ago	Cigna roste, ale náklady a dluh tlačí na marže Cigna těží ze silného růstu Specialty and Care Services a zaměstnavatelského byznysu, ale tlak na náklady, vyšší medical cost ratio a dluh brzdí marže. CI Cigna	FMP Stock News	78
Original source text Key Takeaways Cigna benefits from strong Specialty and Care Services and employer business growth.Cigna's pharmacy strategy, AI initiatives and buybacks support its growth and shareholder value.Rising expenses, a higher medical cost ratio and significant debt pose risks to margin growth. The Cigna Group (CI - Free Report) continues to drive growth on the back of strong segmental performance, improving operating efficiency and shareholder-friendly moves. Its forward P/E of 8.61X is lower than the industry average of 16X. Cigna — with a market capitalization of $73.6 billion — offers a variety of health solutions and insurance products. It operates through two main divisions: Cigna Healthcare and Evernorth Health Services. The company’s shares have gained 1.2% in the year-to-date period compared with the industry average of a 20.3% rise. Courtesy of solid prospects, Cigna currently carries a Zacks Rank #3 (Hold) and Value Score of A. Where Do Estimates for CI Stand?The Zacks Consensus Estimate for Cigna’s 2026 earnings is pegged at $30.50 per share, indicating a 2.2% year-over-year rise. In the past month, it has witnessed eight upward estimate revisions against none in the opposite direction. Furthermore, the consensus mark for revenues is pegged at $288.8 billion for 2026. It beat earnings estimates in each of the past four quarters, with the average surprise being 2.3%. CI’s Growth DriversCigna is benefiting from strong growth in its Specialty and Care Services business, supported by rising specialty-drug utilization and faster adoption of biosimilars and specialty generics. Evernorth’s Specialty and Care Services delivered 22% year-over-year growth in pretax adjusted earnings to $1.1 billion in the second quarter of 2026. Higher generic penetration, operating efficiencies and contributions from Shields Health Solutions, which expands Cigna’s reach across hospitals and health systems, also supported the performance. In the second quarter of 2026, Evernorth Health Services’ adjusted revenues increased 6.3% year over year. Cigna Healthcare is another key growth driver, with the U.S. employer business benefiting from strong client relationships, disciplined pricing and effective care coordination. Second-quarter adjusted revenues increased 9.1% year over year to $11.7 billion, while pretax adjusted earnings rose 17%, supported by favorable medical cost trends and continued membership growth in the employer market. CI is also reshaping its pharmacy benefits business to create a more sustainable growth platform. Its new Signature rebate-free pharmacy model has generated early interest from health plans and employers and is expected to be introduced to Cigna Healthcare’s fully insured plans next year before a broader market launch in 2028. Pharmacy Benefit Services also achieved more than 97% client retention for 2026, while new business secured for 2027 already exceeds the combined level of the previous two selling seasons. Technology and AI are emerging as additional levers for improving care, affordability and efficiency. Cigna’s Pharmacy Forward program is expected to halve the average time to therapy for specialty medications and reduce clinician documentation time by up to 50%. Meanwhile, expanded AI-enabled care coordination is expected to reach 20% more customers with emerging complex health needs. Customers participating in these programs have seen approximately $2,000 in annual medical-cost savings and a 42% reduction in avoidable inpatient stays. Cigna continues to demonstrate a strong commitment to enhancing shareholder value. During the second quarter of 2026, it repurchased approximately 0.9 million shares for about $250 million. Its current dividend yield of 2.24% is higher than the industry average of 2.02%. CI: Risks to WatchHowever, there are some factors that investors should keep a careful eye on. The company’s total benefits and expenses escalated over the last several years due to higher pharmacy and other service costs, medical costs and other benefit expenses. Total benefits and expenses witnessed a year-over-year increase of 6% in the second quarter of 2026. The persistent escalation of expenses might weigh on its margin growth. In the second quarter of 2026, the medical cost ratio deteriorated 130 bps year over year to 84.5%. Cigna has been grappling with a significant debt level over the past several years. As of June 30, 2026, it had a long-term debt of $29.1 billion, significantly higher than the cash balance of $6.3 billion. This is likely to put pressure on the company’s interest expenses. Its net debt to capital is 32.9%, higher than the industry’s average of 18.4%. Stocks to ConsiderSome better-ranked stocks in the Medical space are BrightSpring Health Services, Inc. (BTSG - Free Report) , Globus Medical, Inc. (GMED - Free Report) and Centene Corporation (CNC - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. The Zacks Consensus Estimate for BrightSpring Health Services’ current-year earnings of $1.78 per share has witnessed five upward revisions in the past 30 days against no movement in the opposite direction. BTSG beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 16.1%. The consensus estimate for current-year revenues is pegged at $15.2 billion, suggesting 18.1% year-over-year growth. The Zacks Consensus Estimate for Globus Medical’s current-year earnings of $4.93 per share has witnessed three upward revisions in the past 30 days, against no movement in the opposite direction. GMED Pharmaceuticals beat earnings estimates in each of the trailing four quarters, with the average surprise being 27.9%. The consensus estimate for current-year revenues is pegged at $3.2 billion, suggesting 8.8% year-over-year growth. The Zacks Consensus Estimate for Centene’s current-year earnings of $4.89 per share has witnessed one upward revision in the past seven days, against no movement in the opposite direction. CNC beat earnings estimates in each of the trailing four quarters, with an average surprise of 151.3%. The consensus estimate for current-year revenues is pegged at $196.3 billion, suggesting 0.8% year-over-year growth.
	Saved 2026-08-01 14:02 1mo ago Published 2026-08-01 03:48 1mo ago	Bank of America zvýšila podíl v Cigna, upravený zisk překonal odhad Bank of America Corp DE ve 1. čtvrtletí zvýšila podíl v Cigna Group o 8,8 % na 3 182 083 akcií v hodnotě 848,8 mil. USD. Cigna zároveň oznámila upravený zisk 7,78 USD na akcii, nad odhadem analytiků 7,60 USD. CI Cigna	FMP Stock News	72
Original source text Posted by Defense World Staff on Aug 1st, 2026 Bank of America Corp DE grew its stake in shares of Cigna Group (NYSE:CI – Free Report) by 8.8% in the first quarter, according to its most recent filing with the SEC. The fund owned 3,182,083 shares of the health services provider’s stock after acquiring an additional 256,677 shares during the period. Bank of America Corp DE owned about 1.20% of Cigna Group worth $848,821,000 at the end of the most recent reporting period. Several other large investors have also modified their holdings of the stock. Evercore Wealth Management LLC raised its holdings in Cigna Group by 2.8% during the 1st quarter. Evercore Wealth Management LLC now owns 1,301 shares of the health services provider’s stock worth $347,000 after buying an additional 35 shares during the period. Cary Street Partners Investment Advisory LLC boosted its holdings in shares of Cigna Group by 11.0% in the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 363 shares of the health services provider’s stock worth $100,000 after buying an additional 36 shares during the period. OLD National Bancorp IN increased its position in shares of Cigna Group by 3.7% in the fourth quarter. OLD National Bancorp IN now owns 1,031 shares of the health services provider’s stock worth $284,000 after acquiring an additional 37 shares in the last quarter. IHT Wealth Management LLC increased its position in shares of Cigna Group by 2.5% in the fourth quarter. IHT Wealth Management LLC now owns 1,535 shares of the health services provider’s stock worth $423,000 after acquiring an additional 38 shares in the last quarter. Finally, Whetstone Capital Advisors LLC raised its holdings in shares of Cigna Group by 4.9% during the fourth quarter. Whetstone Capital Advisors LLC now owns 829 shares of the health services provider’s stock valued at $228,000 after acquiring an additional 39 shares during the period. 86.99% of the stock is owned by institutional investors. Analyst Ratings Changes A number of equities analysts recently commented on the stock. Sanford C. Bernstein raised their price objective on shares of Cigna Group from $371.00 to $381.00 and gave the stock an “outperform” rating in a research note on Thursday, July 9th. Guggenheim raised their target price on Cigna Group from $338.00 to $361.00 and gave the stock a “buy” rating in a research report on Friday. Morgan Stanley lifted their price target on Cigna Group from $355.00 to $361.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. Robert W. Baird set a $362.00 price target on Cigna Group in a research report on Friday. Finally, Jefferies Financial Group reduced their price objective on Cigna Group from $333.00 to $330.00 and set a “buy” rating for the company in a research note on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $341.60. Check Out Our Latest Stock Analysis on Cigna Group Cigna Group News Roundup Here are the key news stories impacting Cigna Group this week: Positive Sentiment: Cigna reported adjusted second-quarter earnings of $7.78 per share, above the roughly $7.60 consensus estimate, while revenue rose 7% year over year to approximately $71.7 billion. Cigna Healthcare revenue increased 9%, and Evernorth Health Services revenue grew 6%. Cigna Q2 results and outlook Positive Sentiment: Management raised its 2026 adjusted earnings outlook to at least $30.45 per share, implying approximately 10% earnings growth, supported by strength across the healthcare and pharmacy-benefit businesses. Cigna raises annual profit forecast Positive Sentiment: Analyst sentiment remains constructive: Barclays raised its price target from $304 to $310 while retaining an “equal weight” rating. A separate analysis highlighted CI’s discounted valuation, ongoing share repurchases, strong cash generation, and $1.56-per-share dividend. Cigna valuation analysis Neutral Sentiment: The earnings beat was accompanied by revenue that was slightly below some analyst estimates, and Barclays’ “equal weight” stance suggests the improved outlook may already be partly reflected in the stock. Negative Sentiment: Cigna expects lower growth in prescriptions for popular GLP-1 drugs. Because these treatments are a significant growth area for pharmacy services, slower utilization could temper future revenue and profit expansion. Cigna GLP-1 prescription outlook Negative Sentiment: Elevated medical costs and higher pharmacy expenses remain industrywide risks. Those pressures may explain why investors initially treated the guidance increase cautiously despite Cigna’s higher profit and broad-based operating growth. Insider Buying and Selling In other Cigna Group news, CEO David Cordani sold 201,878 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $292.82, for a total transaction of $59,113,915.96. Following the completion of the sale, the chief executive officer owned 34,337 shares of the company’s stock, valued at $10,054,560.34. This represents a 85.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Jamie G. Kates sold 899 shares of Cigna Group stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $298.61, for a total transaction of $268,450.39. Following the completion of the transaction, the chief accounting officer directly owned 2,368 shares in the company, valued at approximately $707,108.48. This represents a 27.52% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.60% of the stock is owned by corporate insiders. Cigna Group Trading Down 2.9% Cigna Group stock opened at $279.27 on Friday. The company has a debt-to-equity ratio of 0.68, a current ratio of 0.76 and a quick ratio of 0.73. The company has a market capitalization of $73.88 billion, a price-to-earnings ratio of 11.55, a PEG ratio of 1.11 and a beta of 0.29. Cigna Group has a one year low of $239.51 and a one year high of $315.47. The company’s fifty day moving average price is $286.62 and its two-hundred day moving average price is $281.10. Cigna Group (NYSE:CI – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The health services provider reported $7.78 earnings per share for the quarter, topping analysts’ consensus estimates of $7.60 by $0.18. The company had revenue of $70.04 billion during the quarter, compared to analysts’ expectations of $70.14 billion. Cigna Group had a return on equity of 19.75% and a net margin of 2.27%.The business’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $7.20 earnings per share. Cigna Group has set its FY 2026 guidance at 30.450- EPS. On average, analysts forecast that Cigna Group will post 30.4 earnings per share for the current fiscal year. Cigna Group Announces Dividend The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Investors of record on Tuesday, September 8th will be issued a $1.56 dividend. This represents a $6.24 annualized dividend and a yield of 2.2%. The ex-dividend date is Tuesday, September 8th. Cigna Group’s payout ratio is 26.45%. About Cigna Group (Free Report) Cigna Group (NYSE: CI) is a global health services company that offers a broad portfolio of healthcare products and insurance solutions for individuals, employers, and governments. Its core businesses include medical and behavioral health plans, dental and vision coverage, pharmacy benefit management, and supplemental health products. Cigna serves a mix of commercial, Medicare, and Medicaid customers and provides workplace benefits such as group health plans and disability and life benefits for employers. In addition to traditional insurance products, Cigna operates health services and care-delivery platforms designed to manage costs and improve outcomes. See Also Five stocks we like better than Cigna Group Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case Apple’s Record Quarter Could Not Outrun Its Guidance Problem McKesson’s Compounding Keeps Adding Up Want to see what other hedge funds are holding CI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cigna Group (NYSE:CI – Free Report). Receive News & Ratings for Cigna Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna Group and related companies with MarketBeat.com's FREE daily email newsletter. « PREVIOUS HEADLINEBank of America Corp DE Sells 97,969 Shares of Vanguard Large-Cap ETF $VV NEXT HEADLINE »Axiom Investment Management LLC Makes New $677,000 Investment in Gilead Sciences, Inc. $GILD
	Saved 2026-07-30 11:32 1mo ago Published 2026-07-30 06:00 1mo ago	The Cigna Group zvýšila tržby i výhled zisku The Cigna Group ve 2. čtvrtletí zvýšila tržby o 7 % na 71,7 miliardy USD a upravený zisk z operací na akcii na 7,78 USD. Zároveň zvýšila celoroční výhled upraveného zisku z operací na akcii na nejméně 30,45 USD. CI Cigna	FMP Stock News	92
Original source text Total revenues for the second quarter 2026 increased 7% to $71.7 billion Shareholders' net income for the second quarter 2026 was $1.7 billion, or $6.29 per share Adjusted income from operations1 for the second quarter 2026 was $2.1 billion, or $7.78 per share 2026 outlook2 for adjusted income from operations1,2 increased to at least $30.45 per share2 , /PRNewswire/ -- Global health company The Cigna Group (NYSE: CI) today reported second quarter 2026 results, reflecting solid operational performance across its diversified portfolio of businesses. "Our purpose is to improve the lives of each and every customer and patient we serve," said Brian C. Evanko, President and Chief Executive Officer of The Cigna Group. "By harnessing technology, data and AI to deliver more personalized experiences, improve access and lower costs, we are creating greater value every day. Our strong second quarter results reflect continued progress against these priorities and demonstrate the effectiveness of our strategy and execution." Shareholders' net income for second quarter 2026 was $1.7 billion, or $6.29 per share compared to $1.5 billion, or $5.71 per share, for second quarter 2025, primarily reflecting growth in Cigna Healthcare. The Cigna Group's adjusted income from operations1 for second quarter 2026 was $2.1 billion, or $7.78 per share, compared with $1.9 billion, or $7.20 per share, for second quarter 2025. A reconciliation of shareholders' net income to adjusted income from operations1 is provided on the following page and on Exhibit 1 of this earnings release. CONSOLIDATED HIGHLIGHTS The following table includes highlights of results and reconciliations of total revenues to adjusted revenues3 and shareholders' net income to adjusted income from operations1: Consolidated Financial Results (unaudited, dollars in millions): Three Months Ended Six Months Ended June 30, March 31, June 30, 2026 2025 2026 2026 Total Revenues $ 71,668 $ 67,178 $ 68,494 $ 140,162 Net Investment Results from Equity Method Investments3 (110) (44) 23 (87) Adjusted Revenues3 $ 71,558 $ 67,134 $ 68,517 $ 140,075 Consolidated Earnings, net of taxes Shareholders' Net Income $ 1,660 $ 1,532 $ 1,654 $ 3,314 Net Investment (Gains)1 (55) (103) (233) (288) Amortization of Acquired Intangible Assets1 296 330 315 611 Special Items1 153 171 322 475 Adjusted Income from Operations1 $ 2,054 $ 1,930 $ 2,058 $ 4,112 Shareholders' Net Income, per share $ 6.29 $ 5.71 $ 6.26 $ 12.55 Adjusted Income from Operations1, per share $ 7.78 $ 7.20 $ 7.79 $ 15.58 Total revenues for second quarter 2026 increased 7% relative to second quarter 2025, driven by growth in both Evernorth Health Services and Cigna Healthcare. Adjusted income from operations1 for second quarter 2026 increased 6% relative to second quarter 2025, driven by higher contributions from Cigna Healthcare. The SG&A expense ratio4 and adjusted SG&A expense ratio4 were 4.8% and 4.6% for second quarter 2026, compared to 5.1% and 4.9%, respectively, in second quarter 2025, primarily reflecting operating efficiency. Year to date through July 29, 2026, the company repurchased 0.9 million shares of common stock for approximately $250 million. CUSTOMER RELATIONSHIPS The following table summarizes The Cigna Group's medical customers and overall customer relationships: Customer Relationships (in thousands): As of the Periods Ended June 30, March 31, December 31, 2026 2025 2026 2025 Total Pharmacy Customers 118,243 121,892 121,020 123,603 U.S. Healthcare 16,678 16,355 16,623 16,423 International Health 1,735 1,691 1,711 1,695 Total Medical Customers5 18,413 18,046 18,334 18,118 Behavioral Care 27,621 23,852 27,558 28,269 Dental 18,488 18,446 18,558 18,438 Total Customer Relationships 182,765 182,236 185,470 188,428 Total customer relationships at June 30, 2026 decreased 3% from December 31, 2025 to 182.8 million. Total pharmacy customers at June 30, 2026 decreased 4% from December 31, 2025 to 118.2 million, reflecting expected client transitions and lower membership from health plan clients. Total medical customers5 at June 30, 2026 increased 2% from December 31, 2025 to 18.4 million reflecting growth in Middle and Select markets, partially offset by lower membership in National Accounts. HIGHLIGHTS OF SEGMENT RESULTS See Exhibit 1 for a reconciliation of adjusted income from operations1 to shareholders' net income. Evernorth Health Services This segment includes the Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the health care system to work better and help people live healthier lives. Pharmacy Benefit Services drives high-quality, cost-effective pharmacy care through various services such as drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management and access to our home delivery pharmacy. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, as well as clinical programs to help our clients drive better whole-person health outcomes through care services. Financial Results (dollars in millions): Three Months Ended Six Months Ended June 30, March 31, June 30, 2026 2025 2026 2026 Total Adjusted Revenues Pharmacy Benefit Services $ 34,496 $ 31,954 $ 33,002 $ 67,498 Specialty and Care Services $ 26,972 $ 25,871 $ 25,440 $ 52,412 Adjusted Revenues3 $ 61,468 $ 57,825 $ 58,442 $ 119,910 Adjusted Income from Operations, Pre-Tax Pharmacy Benefit Services $ 609 $ 833 $ 394 $ 1,003 Specialty and Care Services $ 1,054 $ 863 $ 1,072 $ 2,126 Adjusted Income from Operations, Pre-Tax1 $ 1,663 $ 1,696 $ 1,466 $ 3,129 Margin, Pre-Tax6 2.7 % 2.9 % 2.5 % 2.6 % Evernorth Health Services second quarter 2026 adjusted revenues3 increased 6% and adjusted income from operations, pre-tax1, decreased 2%, relative to second quarter 2025. For Pharmacy Benefit Services second quarter 2026 relative to second quarter 2025: Adjusted revenues3 increased 8% primarily due to drug mix. Adjusted income from operations, pre-tax1, decreased 27%, primarily reflecting client-focused initiatives, including large client contract renewals, and customer-focused initiatives, consistent with prior commentary. For Specialty and Care Services second quarter 2026 relative to second quarter 2025: Adjusted revenues3 increased 4% reflecting strong specialty volume growth. Adjusted income from operations, pre-tax1, increased 22% primarily reflecting strong organic growth in specialty businesses, including higher generic and biosimilar adoption which benefits clients and patients by delivering lower costs, and operating efficiencies. Cigna Healthcare This segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. U.S. Healthcare provides medical plans and other benefits and solutions for insured and self-insured clients as well as individual and family plan customers. International Health provides health care solutions in our international markets, as well as health solutions for globally mobile individuals and employees of multinational organizations. In April 2026, the Company announced its planned exit from the Individual and Family Plans medical business as of January 1, 2027. Financial Results (dollars in millions): Three Months Ended Six Months Ended June 30, March 31, June 30, 2026 2025 2026 2026 Adjusted Revenues3,7 $ 11,728 $ 10,754 $ 11,477 $ 23,205 Adjusted Income from Operations, Pre-Tax1 $ 1,276 $ 1,094 $ 1,514 $ 2,790 Margin, Pre-Tax6 10.9 % 10.2 % 13.2 % 12.0 % Second quarter 2026 adjusted revenues3 increased 9% relative to second quarter 2025, primarily reflecting premium rate increases to cover expected increases in medical costs. Second quarter 2026 adjusted income from operations, pre-tax1, increased 17% relative to second quarter 2025, primarily due to an improved margin within our U.S. Employer business. The Cigna Healthcare MCR4 was 84.5% for second quarter 2026, compared to 83.2% for second quarter 2025, primarily reflecting higher prior year risk adjustment benefits within our Individual and Family Plans business recognized in second quarter 2025. Cigna Healthcare net medical costs payable8 was $5.09 billion at June 30, 2026, $4.78 billion at March 31, 2026, and $4.49 billion at June 30, 2025. The sequential increase reflects typical stop loss seasonality. Favorable prior year reserve development on a gross pre-tax basis was $268 million and $297 million for the six months ended June 30, 2026 and 2025, respectively. Corporate and Other Operations Corporate reflects interest expense, amounts not allocated to operating segments and includes intersegment eliminations. Other Operations is comprised of Corporate Owned Life Insurance ("COLI"), the Company's run-off operations and other non-strategic businesses. Financial Results (dollars in millions): Three Months Ended Six Months Ended June 30, March 31, June 30, 2026 2025 2026 2026 Adjusted (Loss) from Operations, Pre-Tax1 $ (389) $ (357) $ (377) $ (766) 2026 OUTLOOK2 The Cigna Group's outlook for full year 2026 consolidated adjusted income from operations1,2 is at least $30.45 per share2. Additionally, this outlook includes the impact of expected future share repurchases and anticipated 2026 dividends. (dollars in millions, except where noted and per share amounts) 2026 Consolidated Metrics Projection for Full Year Ending December 31, 2026 Change from Prior Projection Adjusted Income from Operations, per share1,2 at least $30.45 +$0.10 Evernorth Adjusted Income from Operations, Pre-Tax1,2 at least $6,900 Cigna Healthcare Adjusted Income from Operations, Pre-Tax1,2 at least $4,550 +$25 Cigna Healthcare Medical Care Ratio2,4 83.7% to 84.7% The foregoing statements represent the Company's current estimates of The Cigna Group's 2026 consolidated and segment adjusted income from operations1,2 and other key metrics as of the date of this release. Actual results may differ materially depending on a number of factors. Investors are urged to read the Cautionary Note Regarding Forward-Looking Statements included in this release. Management does not assume any obligation to update these estimates. This quarterly earnings release and the Quarterly Financial Supplement are available on The Cigna Group's website in the Investor Relations section (https://investors.thecignagroup.com/overview/default.aspx). Management will be hosting a conference call to review second quarter 2026 results and discuss full year 2026 outlook beginning today at 8:30 a.m. ET. A link to the conference call is available in the Investor Relations section of The Cigna Group's website located at https://investors.thecignagroup.com/events-and-presentations/default.aspx. The call-in numbers for the conference call are as follows: Live Call (888) 566-1889 (Domestic) (773) 799-3989 (International) Passcode: 07302026 Replay (866) 405-7290 (Domestic) (203) 369-0603 (International) It is strongly suggested you dial in to the conference call by 8:15 a.m. ET. About The Cigna Group The Cigna Group (NYSE: CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under Evernorth Health Services, Cigna Healthcare, or its subsidiaries. The Cigna Group maintains sales capabilities in more than 30 markets and jurisdictions, and has over 180 million customer relationships around the world. Learn more at thecignagroup.com. Notes: 1. Adjusted income (loss) from operations is a principal financial measure of profitability used by The Cigna Group's management because it presents the underlying results of operations of the Company's businesses and facilitates analysis of trends in underlying revenue, expenses and shareholders' net income. Adjusted income (loss) from operations is defined as shareholders' net income (or income before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of normal, recurring operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated adjusted income (loss) from operations is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders' net income. See Exhibit 1 for a reconciliation of consolidated adjusted income from operations to shareholders' net income. 2. Management is not able to provide a reconciliation of adjusted income from operations to shareholders' net income, on a forward-looking basis because it is unable to predict, without unreasonable effort, certain components thereof including (i) future net investment results and (ii) future special items. These items are inherently uncertain and depend on various factors, many of which are beyond The Cigna Group's control. As such, any associated estimate and its impact on shareholders' net income and total revenues could vary materially. The Company's outlook excludes the potential effects of any other business combinations that may occur after the date of this earnings release. The Company's outlook includes the potential effects of expected future share repurchases and anticipated 2026 dividends. The timing and actual number of shares repurchased will depend on a variety of factors, including price, general business and market conditions, and alternate uses of capital. The share repurchase program may be effected through open market purchases in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, including through Rule 10b5-1 trading plans, or privately negotiated transactions. The program may be suspended or discontinued at any time. 3. Adjusted revenues is used by The Cigna Group's management because it facilitates analysis of trends in underlying revenue. The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of normal, recurring operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business. Adjusted revenues is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, total revenues. See Exhibit 1 for a reconciliation of consolidated adjusted revenues to total revenues. 4. Operating ratios are defined as follows: The Cigna Healthcare medical care ratio ("MCR") represents medical costs as a percentage of premiums for all Cigna Healthcare risk products provided through guaranteed cost or experience-rated funding arrangements. Changes in percentages may be expressed in basis points ("bps"). SG&A expense ratio on a GAAP basis for the second quarter 2026 represents enterprise selling, general and administrative expenses of $3,470 million as a percentage of total revenue of $71.7 billion at a consolidated level. SG&A expense ratio on a GAAP basis for the second quarter 2025 represents enterprise selling, general and administrative expenses of $3,433 million as a percentage of total revenue of $67.2 billion at a consolidated level. Adjusted SG&A expense ratio for the second quarter 2026 represents enterprise selling, general and administrative expenses of $3,290 million excluding special items of $180 million as a percentage of adjusted revenue at a consolidated level. Adjusted SG&A expense ratio for the second quarter 2025 represents enterprise selling, general and administrative expenses of $3,271 million excluding special items of $162 million as a percentage of adjusted revenue at a consolidated level. 5. Customer relationships are defined as follows: Total medical customers includes individuals who meet any one of the following criteria: (i) are covered under a medical insurance policy, managed care arrangement, or administrative services agreement issued by Cigna Healthcare; (ii) have access to Cigna Healthcare's provider network for covered services under their medical plan; or (iii) have medical claims that are administered by Cigna Healthcare. 6. Margin, pre-tax, is calculated by dividing adjusted income (loss) from operations, pre-tax by adjusted revenues for each segment. 7. The Cigna Group owns noncontrolling interests in certain operating joint ventures. As such, the adjusted revenues for the Cigna Healthcare segment only include the Company's share of the joint ventures' earnings reported in Fees and Other Revenues using the equity method of accounting under GAAP. 8. Medical costs payable within the Cigna Healthcare segment are presented net of reinsurance and other recoverables. The gross medical costs payable balance was $5.23 billion as of June 30, 2026, $4.92 billion as of March 31, 2026, and $4.64 billion as of June 30, 2025. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This press release, and oral statements made in connection with this release, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on The Cigna Group's current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements concerning our projected outlook for 2026 (including adjusted revenues; adjusted income from operations, including on a per share, and segment basis; adjusted SG&A expense ratio; adjusted effective tax rate; cash flow from operations; capital expenditures; shareholder dividends; weighted average shares outstanding; medical care ratio; and total medical customers); future financial or operating performance, including our ability to improve the health and vitality of those we serve; future growth, business strategy and strategic or operational initiatives, including our ability to successfully implement actions across our business to strengthen our platform and build a more sustainable model for healthcare; economic, regulatory or competitive environments; capital deployment plans and amounts available for future deployment; our prospects for growth in the coming years; and other statements regarding The Cigna Group's future beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You may identify forward-looking statements by the use of words such as "believe," "expect," "project," "plan," "intend," "anticipate," "estimate," "predict," "potential," "may," "should," "will" or other words or expressions of similar meaning, although not all forward-looking statements contain such terms. Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to manage health care costs and respond to price competition, inflation and other pressures that could compress our margins or result in premiums that are insufficient to cover the cost of services delivered to our customers; our ability to compete effectively, differentiate our products and services from those of our competitors and adapt to changes in an evolving and rapidly changing industry; our ability to develop and effectively implement products and services to improve the accessibility, affordability and transparency of health care; changes in drug pricing or industry pricing benchmarks; our ability to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; the potential for actual claims to exceed our estimates related to expected medical claims; our ability to develop and maintain satisfactory relationships with health care payors, physicians, hospitals, other health service providers and with producers and consultants; potential liability in connection with managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities; uncertainties surrounding participation in government-sponsored programs and providing services to payors who participate in government-sponsored programs; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; compliance with applicable privacy, security and data laws, regulations and standards; the outcome of litigation, regulatory audits and investigations; compliance costs and potential failure of our prevention, detection and control systems; our ability to invest in and properly maintain our information technology and other business systems; our ability to prevent or contain effects of a potential cyberattack or other privacy or data security incident; risks related to our use of artificial intelligence and machine learning; dependence on success of relationships with third parties; risk of significant disruption within our operations or among key suppliers or third parties; political, legal, operational, regulatory, economic and other risks that could affect our multinational operations, including currency exchange rates; risks related to strategic transactions and realization of the expected benefits of such transactions, as well as integration or separation difficulties or underperformance relative to expectations which could lead to an impairment charge; our ability to achieve our strategic and operational initiatives; unfavorable economic and market conditions, the risk of a recession or other economic downturn and resulting impact on employment metrics, stock market or changes in interest rates; risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our significant indebtedness and the potential for further indebtedness in the future; credit risk related to our reinsurers; as well as more specific risks and uncertainties discussed in our most recent report on Form 10-K and subsequent reports on Forms 10-Q and 8-K available through the Investor Relations section of www.thecignagroup.com. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. The Cigna Group undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law. THE CIGNA GROUP Exhibit 1 COMPARATIVE SUMMARY OF FINANCIAL RESULTS (unaudited) Three Months Ended Six Months Ended Three Months Ended June 30, June 30, March 31, (Dollars in millions, except per share amounts) 2026 2025 2026 2025 2026 REVENUES Pharmacy revenues $ 57,172 $ 53,649 $ 111,209 $ 102,282 $ 54,037 Premiums 9,859 9,156 19,671 21,892 9,812 Fees and other revenues 4,365 4,137 8,808 8,032 4,443 Net investment income 272 236 474 474 202 Total revenues 71,668 67,178 140,162 132,680 68,494 Net investment results from certain equity method investments (110) (44) (87) (94) 23 Adjusted revenues (1) $ 71,558 $ 67,134 $ 140,075 $ 132,586 $ 68,517 Shareholders' net income $ 1,660 $ 1,532 $ 3,314 $ 2,855 $ 1,654 Pre-tax adjusted income (loss) from operations by segment Evernorth Health Services $ 1,663 $ 1,696 $ 3,129 $ 3,130 $ 1,466 Cigna Healthcare 1,276 1,094 2,790 2,381 1,514 Corporate and Other Operations (389) (357) (766) (768) (377) Adjusted income tax expense (496) (503) (1,041) (973) (545) Consolidated after-tax adjusted income from operations $ 2,054 $ 1,930 $ 4,112 $ 3,770 $ 2,058 Weighted average shares (in thousands) 263,962 268,154 263,990 270,540 264,017 Common shares outstanding (in thousands) 264,154 266,901 264,498 SHAREHOLDERS' EQUITY at June 30, $ 42,620 $ 40,214 SHAREHOLDERS' EQUITY PER SHARE at June 30, $ 161.35 $ 150.67 Three Months Ended Six Months Ended Three Months Ended June 30, June 30, March 31, 2026 2025 2026 2025 2026 (Dollars in millions, except per share amounts) Pre-tax After-tax Pre-tax After-tax Pre-tax After-tax Pre-tax After-tax Pre-tax After-tax SHAREHOLDERS' NET INCOME Shareholders' net income $ 1,660 $ 1,532 $ 3,314 $ 2,855 $ 1,654 Adjustments to reconcile to adjusted income from operations Net investment (gains) (2) $ (41) (55) $ (96) (103) $ (276) (288) $ (144) (151) $ (235) (233) Amortization of acquired intangible assets 389 296 422 330 779 611 844 666 390 315 Special Items Strategic optimization program 70 53 129 98 450 343 344 261 380 290 Integration and transaction-related costs 34 26 74 56 69 53 290 220 35 27 Charges (benefits) associated with litigation matters 77 60 — — 66 52 — — (11) (8) Deferred tax expenses, net — 17 — 17 — 33 — 34 — 16 (Gain) on sale of businesses (6) (3) — — (6) (6) (41) (115) — (3) Adjusted income from operations (3) $ 2,054 $ 1,930 $ 4,112 $ 3,770 $ 2,058 DILUTED EARNINGS PER SHARE Shareholders' net income $ 6.29 $ 5.71 $ 12.55 $ 10.55 $ 6.26 Adjustments to reconcile to adjusted income from operations Net investment (gains) (2) $ (0.16) (0.21) $ (0.36) (0.38) $ (1.05) (1.09) $ (0.53) (0.56) $ (0.89) (0.88) Amortization of acquired intangible assets 1.48 1.12 1.57 1.23 2.96 2.32 3.12 2.47 1.48 1.19 Special Items Strategic optimization program 0.27 0.20 0.48 0.37 1.70 1.29 1.27 0.97 1.44 1.10 Integration and transaction-related costs 0.13 0.10 0.28 0.21 0.26 0.20 1.07 0.81 0.13 0.10 Charges (benefits) associated with litigation matters 0.28 0.23 — — 0.25 0.20 — — (0.04) (0.03) Deferred tax expenses, net — 0.06 — 0.06 — 0.13 — 0.13 — 0.06 (Gain) on sale of businesses (0.02) (0.01) — — (0.02) (0.02) (0.15) (0.43) — (0.01) Adjusted income from operations (3) $ 7.78 $ 7.20 $ 15.58 $ 13.94 $ 7.79 (1) Adjusted revenues is defined as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. These items are excluded because they are not indicative of past or future underlying performance of our businesses. (2) Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income. (3) Adjusted income (loss) from operations is defined as shareholders' net income (or income before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding the following adjustments: net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] SOURCE The Cigna Group
	Saved 2026-07-27 18:40 1mo ago Published 2026-07-27 13:36 1mo ago	Cigna čeká vyšší výnosy, EPS i méně pojištěných klientů Cigna čeká za 2. čtvrtletí vyšší výnosy i EPS, ale počet pojištěných zdravotních klientů má klesnout na 3,7 milionu z 3,8 milionu před rokem. CI Cigna	FMP Stock News	78
Original source text Key Takeaways Cigna is expected to post higher Q2 revenues and EPS, with Evernorth and pharmacy sales supporting growth.CI's insured medical customers are projected to decline to 3.7 million, while MCR is expected to rise.Evernorth pre-tax adjusted income is expected to decline even as segment revenues are likely to increase. The Cigna Group (CI - Free Report) is set to report second-quarter 2026 results on July 30, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $7.58 per share on revenues of $71.4 billion. The second-quarter earnings estimate remained stable over the past 30 days. The bottom-line projection indicates a year-over-year increase of 5.3%. Also, the Zacks Consensus Estimate for quarterly revenues suggests year-over-year growth of 6.4%. Image Source: Zacks Investment Research For full-year 2026, the Zacks Consensus Estimate for Cigna’s revenues is pegged at $287.1 billion, implying an increase of 4.5% year over year. Also, the consensus mark for 2026 EPS is pegged at $30.39, signaling growth of 1.8% year over year. Cigna beat the earnings estimates in each of the last four quarters, with the average surprise being 1.9%. This is depicted in the figure below. Q2 Earnings Whispers for CignaOur proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. However, that’s not the case here. CI currently has an Earnings ESP of 0.00% and a Zacks Rank #3. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. What’s Shaping Cigna’s Q2 Results?The Zacks Consensus Estimate for pharmacy revenues indicates a 6.6% improvement from the prior-year quarter’s number. Also, the consensus estimate for premiums revenues signals 8.1% year-over-year growth. The consensus mark for revenues from the overall Evernorth Health Services segment is pegged at $61.6 billion, indicating 6.5% growth from the prior-year quarter’s figure. The Zacks Consensus Estimate for Cigna Healthcare revenues suggests a 5.4% increase. The consensus estimate for pre-tax adjusted income from Cigna Healthcare indicates a 12.3% increase from a year ago. However, the consensus mark for fees and other revenues implies a 1.3% decrease from the year-ago quarter. The consensus mark for Cigna’s total insured healthcare medical customers is pegged at 3.7 million, indicating a decline from 3.8 million a year ago. The consensus estimate for pre-tax adjusted income from Evernorth indicates a 4.4% decrease from a year ago. The consensus mark for the medical care ratio or MCR is pegged at 84.45%, up from 83.20% a year ago. Stocks That Warrant a LookWhile an earnings beat looks uncertain for Cigna, here are some companies from the broader Medical space that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this time around: ProMIS Neurosciences, Inc. (PMN - Free Report) has an Earnings ESP of +13.30% and a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here. The Zacks Consensus Estimate calls for ProMIS to report a loss of $1.45 per share for the to-be-reported quarter, indicating an 80% year-over-year improvement. PMN has witnessed one upward revision against no downward movement over the past 60 days. Cardinal Health, Inc. (CAH - Free Report) has an Earnings ESP of +1.24% and a Zacks Rank of 2 at present. The Zacks Consensus Estimate for Cardinal Health’s bottom line for the to-be-reported quarter predicts 16.4% year-over-year growth. Its earnings beat estimates in each of the past four quarters, with an average surprise of 10.3%. The consensus estimate for CAH’s revenues is pegged at $65.6 billion, a 9.1% increase from the year-ago period. Alcon Inc. (ALC - Free Report) has an Earnings ESP of +3.13% and a Zacks Rank of 3 at present. The Zacks Consensus Estimate for Alcon’s bottom line for the to-be-reported quarter indicates a 1.3% increase from a year ago. The company’s earnings beat estimates in three of the trailing four quarters and missed once, with an average surprise of 3.7%. The consensus estimate for ALC’s revenues is pegged at $2.8 billion, signaling a 7.3% increase.
	Saved 2026-07-23 11:23 1mo ago Published 2026-07-23 07:00 1mo ago	Cigna Healthcare rozšiřuje AI podporu pro včasnější identifikaci Cigna Healthcare rozšiřuje AI podporu pro včasnější identifikaci zákazníků s komplexními či chronickými potřebami. Očekává 20% více podpořených klientů a úsporu 200 milionů USD za tři roky. CI Cigna	FMP Stock News	78
Original source text New capabilities will help 20% more customers with complex or chronic health needs access personalized clinical support earlier, reducing medical costs by $200M over three years , /PRNewswire/ -- Cigna Healthcare®, the health benefits division of The Cigna Group (NYSE: CI), is significantly expanding its personalized care management programs through AI-enabled capabilities and predictive analytics that help identify customers who would benefit from earlier support and connect them with clinicians. The expansion will support 20% more customers with emerging, complex or chronic health needs – including cancer, heart disease, kidney disease, high-risk pregnancy, and behavioral health conditions. AI-enabled capacities identify opportunities for personalized outreach and support, while experienced clinicians provide the guidance, care coordination, and expertise needed to help customers navigate their health journey with confidence. More than 1,250 Cigna Healthcare clinicians, including nurses and behavioral health specialists, guide customers as they navigate care, coordinate with multiple providers, and access additional resources. Through these new capabilities, clinicians will help customers address health needs earlier and manage conditions more effectively – reducing medical costs for engaged customers by $2,000 per year on average, resulting in an estimated $200 million in total savings over the next three years. "As costs for hospital care, emergency services, and prescription drugs continue to rise, we are investing in tools and clinical programs that help customers avoid unnecessary hospitalizations, better manage chronic conditions, and reduce the likelihood of more serious and expensive health events later," said Bryan Holgerson, President, Cigna Healthcare U.S. and Executive Vice President, Customer Health Outcomes, The Cigna Group. "By combining predictive analytics, AI-enabled capabilities, and clinical expertise, we can identify health needs earlier and connect more customers with personalized support when it has the greatest impact." Cigna Healthcare's care management programs have demonstrated meaningful results: 95% customer satisfaction among surveyed customers A 42% reduction in avoidable inpatient stays among customers who engage early with care management support Earlier identification of likely breast, colorectal, and lung cancer diagnoses by approximately 55, 46, and 37 days, respectively 72% of customers achieving clinically meaningful improvement in depression symptoms when connected to high-quality behavioral health providers "Health care can be difficult to navigate, especially when someone is facing a new diagnosis or complex condition. Our goal is to make it easier for customers to connect with an experienced Cigna Healthcare clinician who can help them understand their options and make the most of the support available through their health plan," said Dr. Stanley Crittenden, Chief Medical Officer, Cigna Healthcare. "With earlier guidance, we can help customers get the right care at the right time and avoid more serious and costly health complications." How These Enhancements Improve Customer Experience These AI-enabled capabilities help Cigna Healthcare identify opportunities to provide support earlier, personalize engagement, and connect more customers with experienced clinicians. Earlier Identification of Support Opportunities: Advanced predictive models and AI-enabled insights help identify emerging health needs sooner, creating more opportunities to engage customers before a condition becomes more serious. More Personalized Engagement: Customers can connect with clinicians through the channels they prefer, including phone, text, email, and digital tools. These interactions create more opportunities to provide guidance, answer questions, and support healthier outcomes. Greater Access to Expert Clinical Support: AI-enabled capabilities help identify and prioritize engagement opportunities, allowing clinicians to focus more time on helping customers understand their options, coordinate care, and access resources. This work advances the company's commitments to create more connected, personalized health care experiences and complements services such as My Personal Champion, which helps customers navigate the administrative challenges that often accompany complex health conditions, including prior authorizations, claims, and continuity of care. About Cigna Healthcare Cigna Healthcare is a health benefits provider that advocates for better health through every stage of life. We guide our customers through the health care system, empowering them with the information and insight they need to make the best choices for improving their health and vitality. Products and services are provided exclusively by or through operating subsidiaries of The Cigna Group (NYSE:CI), including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Health companies or their affiliates and Express Scripts companies or their affiliates. Such products and services include an integrated suite of health services, such as medical, dental, behavioral health, pharmacy, vision, supplemental benefits, and others. Learn more at www.cignahealthcare.com. MEDIA CONTACT: Gena Madow [email protected] 240.513.5986 SOURCE Cigna Healthcare
	Saved 2026-07-22 20:57 1mo ago Published 2026-07-22 16:30 1mo ago	The Cigna Group vyhlásila čtvrtletní dividendu ve výši 1,56 USD na akcii The Cigna Group vyhlásila čtvrtletní dividendu ve výši 1,56 USD na akcii. Vyplacena bude 23. září 2026 akcionářům, kteří budou zapsáni k 8. září 2026. CI Cigna	FMP Stock News	78
Original source text Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Hamburger menu Send a Release BLOOMFIELD, Conn., July 22, 2026 /PRNewswire/ -- The Board of Directors of The Cigna Group (NYSE: CI) today declared a cash dividend of $1.56 per share of its common stock, payable on September 23, 2026, to shareholders of record as of the close of business on September 8, 2026. About The Cigna Group The Cigna Group (NYSE:CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under Cigna Healthcare, Evernorth Health Services or its subsidiaries. The Cigna Group maintains sales capabilities in more than 30 markets and jurisdictions, and has over 180 million customer relationships around the world. Learn more at thecignagroup.com Investor Relations Contact Ralph Giacobbe 1 (860) 787-7968 [email protected] Media Contact Justine Sessions 1 (860) 810-6523 [email protected] SOURCE The Cigna Group Also from this source
	Saved 2026-07-01 14:02 2mo ago Published 2026-07-01 08:00 2mo ago	Evernorth spouští AI program pro rychlejší specializovanou péči Evernorth spouští Pharmacy Forward, AI program pro rychlejší a personalizovanější specializovanou péči v Accredo Specialty Pharmacy. Projekt má do roku 2028 podpořit investice ve výši 100 milionů USD a zkrátit zpracování receptů. CI Cigna	FMP Stock News	78
Original source text New program introduces AI-enabled capabilities to personalize support, streamline prescription processing, and help patients start and stay on therapy with greater ease and confidence , /PRNewswire/ -- As specialty care becomes more complex, patients need faster, more connected, and personalized support. To help meet that need, Evernorth, the health services division of The Cigna Group (NYSE:CI), today unveiled Pharmacy Forward, a new AI-powered program designed to improve how patients access and experience specialty care. Launching first with Accredo Specialty Pharmacy – which serves patients with chronic and complex specialty conditions through condition-specific Therapeutic Resource Centers (TRCs) – the program is supported by a $100 million investment through 2028. This investment enables care teams to focus more on clinical care and patient outcomes while reducing prescription processing timelines and improving service responsiveness. "Patients navigating complex health conditions need comprehensive, expert support, often during some of the most difficult moments in their lives," said Matt Perlberg, President of the Evernorth Health Services pharmacy and care delivery businesses, including Accredo, and Executive Vice President of Customer Innovation for The Cigna Group. "Pharmacy Forward reflects our commitment to meet patients where they are —delivering an even faster, more seamless experience while ensuring they receive the personalized support and clinical care they deserve." A Smarter, Faster, More Personalized Specialty Pharmacy Experience Pharmacy Forward applies AI across four core areas: clinical care, prescription intake, administration, and medication fulfillment: Care Enablement — Supporting More Coordinated, Insight-Driven Care: Pharmacy Forward is expected to improve medication adherence beyond the industry standard of 80%, helping patients stay on therapy and achieve optimal health outcomes. By integrating clinical data and insights, AI-generated summaries, and predictive analytics, care teams can deliver more connected, informed support. This enables clinicians to proactively identify patients at risk of falling off therapy or experiencing adverse events, empowering earlier intervention, stronger coordination, and an improved patient experience. The program uses AI to free up more time for clinicians to focus on patient care and is expected to reduce clinician documentation time by up to 50%. Experience Accelerators – Improving the Patient Journey in Real Time: Pharmacy Forward uses AI-enabled tools to reach patients earlier in their care journey and deliver more proactive, personalized support. For example, Accredo has implemented AI-enabled scheduling so outreach occurs during patients' preferred call windows. Additionally, Accredo anticipates a 25% increase in use of personalized patient digital pathways, enabling more patients to complete routine steps on their own terms — getting answers faster, starting prescriptions through the app or website, and scheduling therapy more easily. Rx Readiness — Accelerating Time to Therapy: Pharmacy Forward is cutting the time it takes for patients to receive their medication after Accredo receives a prescription in half — helping patients start treatment sooner. By using AI to improve the completeness of prior authorization submissions, identify copay assistance eligibility, and ensure prescriptions are ready earlier in the process, the program is designed to streamline the time it takes to process a prescription and reduce delays in care. One Fulfillment Network — Delivering Medications Faster and More Reliably: Pharmacy Forward will enhance Accredo's ability to ship complex specialty medications from sites as close to a patient's home as possible, ensuring that 90% of patients are within a 1-day or same day ground shipping radius. To enable this, Accredo is expanding capacity, staffing, and capabilities at many of its nearly 40 care facilities to reduce the need for longer ground or air shipments, which are more susceptible to delays from adverse events such as weather. The enhancements will be supported by AI technology, for example, to continuously analyze factors such as patient location, delivery timing, and medication handling requirements to determine the most effective dispensing location. Together, these capabilities represent the next evolution of specialty pharmacy — combining AI, clinical expertise, and operational scale to create a more connected and responsive care experience. The program is expected to generate approximately $400 million in value by the end of 2028, helping make care more coordinated and personalized for the more than one million patients Accredo serves each year. Evernorth expects to extend many of these capabilities to its other pharmacies' operations in the coming years. "AI is enabling us to fundamentally reimagine how we support each patient's journey," said Katya Andresen, Chief Data, Digital and AI Officer, The Cigna Group. "By responsibly combining real-time data, advanced analytics and deep clinical expertise, we can deliver more personalized, proactive support — helping people access the care they need faster and achieve better health outcomes." About Evernorth Health Services Evernorth Health Services is the pharmacy, care, and benefits solutions division of The Cigna Group (NYSE: CI). We create and deliver innovative, flexible, and people-first solutions that solve the most complex health care challenges. Evernorth is home to pioneering brands including Express Scripts, Express Scripts Pharmacy, Accredo, eviCore, and MD Live. We have more than 40,000 employees who work to make health care more affordable, predictable, and simple for the 190 million people we serve. Learn more at evernorth.com. Media Contact Justine Sessions [email protected] 860-810-6523 SOURCE Evernorth
	Saved 2026-06-25 16:46 2mo ago Published 2026-06-25 11:21 2mo ago	Cigna rozšiřuje služby a zvyšuje výhled upraveného EPS Cigna rozšiřuje byznys mimo oblast zdravotního pojištění o lékárenské služby, specializovanou péči a AI. Zároveň zvýšila výhled upraveného EPS pro rok 2026 o 10 centů na nejméně 30,35 USD na akcii. CI Cigna	FMP Stock News	78
Original source text Key Takeaways Cigna is broadening its business with pharmacy services, specialty care and AI-driven solutions.CI raised its 2026 adjusted EPS outlook and is reshaping its portfolio toward higher-growth areas.Evernorth is fueling growth with pharmacy benefits, specialty pharmacy and care services. If you still think of The Cigna Group (CI - Free Report) as just a traditional health insurer, it may be time for a second look. The company is steadily expanding beyond insurance, building a broader healthcare platform centered on pharmacy services, specialty care and AI-powered solutions. The strategy is beginning to deliver results. Evernorth, Cigna's health services business, is driving much of the company's transformation. Its pharmacy benefits, specialty pharmacy and care services businesses are helping deliver more affordable, personalized care. In the first quarter of 2026, Evernorth's adjusted revenues grew 9% year over year to $58.4 billion. Technology is becoming another key growth driver. Cigna is using AI and advanced analytics to streamline prescriptions, identify high-risk patients earlier and improve customer engagement. Its rebate-free Signature pharmacy model aims to lower out-of-pocket drug costs, while AI helps simplify the pharmacy experience. Cigna is also reshaping its portfolio. Investments in CarepathRx and Shields Health Solutions have strengthened its specialty pharmacy business. It also plans to exit the individual exchange business and is reviewing strategic alternatives for eviCore. These moves should help management direct more resources toward its higher-growth businesses. Management's confidence in the strategy is growing. Following a strong first quarter, Cigna raised its 2026 adjusted EPS outlook by 10 cents to at least $30.35 per share. Cigna's push beyond traditional health insurance is still unfolding, but its growing focus on AI, specialty pharmacy and healthcare services is opening new avenues for long-term growth. How Are Cigna's Peers Positioned?Cigna isn't alone in this shift. Peers in the Medical space, like UnitedHealth Group Incorporated (UNH - Free Report) and CVS Health Corporation (CVS - Free Report) are also investing in technology-enabled healthcare services, making innovation a key differentiator across the industry. UnitedHealth is pursuing a similar strategy through Optum, which combines pharmacy services, care delivery and technology. Growth in Optum Rx and commercial fee-based membership supported previous quarter’s results. UNH is also expanding its AI and analytics capabilities while rolling out a transparent, fee-based pharmacy care model. CVS Health is also broadening its healthcare platform through pharmacy services, digital innovation and care delivery. CVS continues to expand AI-powered member engagement and digital onboarding at Aetna while strengthening CVS Caremark and its Health Care Delivery business. Cigna’s Price Performance, Valuation & EstimatesShares of Cigna have risen 1.6% year to date compared with the industry’s 22.8%. growth Image Source: Zacks Investment Research From a valuation standpoint, Cigna trades at a forward price-to-earnings ratio of 8.78X compared with the industry average of 17.75X. CI carries a Value Score of C. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Cigna’s 2026 earnings is pegged at $30.39 per share, implying a 1.8% increase from the year-ago period’s level. Image Source: Zacks Investment Research Cigna currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.